GlaxoSmithKline Moving to Meet Vaccine Needs

Seeing a lucrative market ahead, GlaxoSmithKline plans to introduce five new vaccines in the next five years, including ones addressing cervical cancer, rotavirus, pneumonia, influenza and meningitis.

Glaxo estimates the global market for these vaccines to reach $11 billion to $18 billion in five years, say an AP article.